Ahmed S. Abdelsamie

发表

Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2019, Molecular and Cellular Endocrinology.

Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.

M. Elhefnawi, H. Tokuda, N. Suzuki, 2011, European journal of medicinal chemistry.

First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases.

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2017, Journal of medicinal chemistry.

New thiopyrimidine-benzenesulfonamide conjugates as selective carbonic anhydrase II inhibitors: synthesis, in vitro biological evaluation, and molecular docking studies.

C. Supuran, Ahmed S. Abdelsamie, Ahmed M. El Kerdawy, 2020, Bioorganic & medicinal chemistry.

Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis.

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2022, Journal of medicinal chemistry.

Role of Diffusion-Weighted Magnetic Resonance Imaging in Detecting and Characterizing Benign and Malignant Liver Tumors in Adults

Ahmed S. Abdelsamie, M. Madbouly, M. Hassan, 2021 .

Divergent synthesis and biological evaluation of 2-(trifluoromethyl)pyridines as virulence-attenuating inverse agonists targeting PqsR.

W. Blankenfeldt, A. Scrima, S. Schmelz, 2021, European journal of medicinal chemistry.

Discovery and Characterization of Synthesized and FDA-Approved Inhibitors of Clostridial and Bacillary Collagenases

S. Wessler, C. Huber, H. Brandstetter, 2022, Journal of medicinal chemistry.

Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis.

R. Hartmann, M. Menger, G. Vollmer, 2019, Journal of medicinal chemistry.

Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity.

Salwa M. Soliman, G. Wolber, Mamdouh M. Ali, 2014, European journal of medicinal chemistry.

Synthesis and studying the antitumor activity of novel 5-(2-methylbenzimidazol-5-yl)-1,3,4-oxadiazole-2(3H)-thiones

S. Kerwin, Ahmed S. Abdelsamie, Mireya L Rodriguez, 2010 .

Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor.

Salwa M. Soliman, G. Wolber, H. Tokuda, 2013, European journal of medicinal chemistry.

First Structure-Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme.

G. Klebe, A. Heine, J. Adamski, 2016, Journal of medicinal chemistry.

Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study.

M. Menger, M. Laschke, Mohamed Salah, 2017, European journal of medicinal chemistry.

Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof‐of‐Principle

R. Hartmann, B. Tümmler, D. Jahn, 2023, Advanced science.

Part 1. Synthesis, Cancer Chemopreventive Activity and Molecular Docking Study of Novel Quinoxaline Derivatives.

M. Elhefnawi, H. Tokuda, N. Suzuki, 2011 .

A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms

R. Hartmann, R. Bals, W. Blankenfeldt, 2021, Advanced science.

Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs.

Hamed I. Ali, Mamdouh M. Ali, Abeer E E Mahmoud, 2017, European journal of medicinal chemistry.

Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.

R. Hartmann, M. Menger, T. Pohlemann, 2019, Journal of medicinal chemistry.

Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.

R. Hartmann, M. Hamed, Mohamed Salah, 2019, European journal of medicinal chemistry.

Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy.

R. Hartmann, M. Menger, M. Laschke, 2018, Journal of medicinal chemistry.

Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model

R. Hartmann, G. Vollmer, Sophie Pählig, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer.

P. Jagodziński, R. Hartmann, G. Mangiatordi, 2021, ACS medicinal chemistry letters.

Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.

R. Hartmann, Ahmed S. Abdelsamie, M. Frotscher, 2014, European journal of medicinal chemistry.

Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.

Ahmed S. Abdelsamie, M. Frotscher, Emmanuel Bey, 2015, European journal of medicinal chemistry.

Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections

C. Beisswenger, C. Lehr, B. Loretz, 2023, ACS central science.